Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI in Metastatic Colorectal Cancer
NCT00080951Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2004
- Primary completion
- Apr 2005
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, irinotecan, folinic acid and oxaliplatin in metastatic colorectal cancer (mCRC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Tumor Response Rate up to 5 years. Started Mar 2004; status: completed.
02
Drugs
fluorouracilirinotecanfolinic acidoxaliplatin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00080951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080951.